摘要
目的评估莫雷西嗪治疗阵发性心房颤动（房颤）患者的有效性和不良反应以及其对房颤负荷的影响。方法入选阵发性房颤患者212例，给莫雷西嗪单药干预，并随访观察治疗1、6、12个月后房颤的再发情况、负荷量和不良反应。结果服用莫雷西嗪1、6、12个月房颤再发率仅34％、32％、35％；用药前与用药后1、6、12个月平均心率，最大心率和最小心率均无明显变化，房颤负荷均有明显下降，并未见死亡和恶性室性心律失常。结论莫雷西嗪可以作为预防、治疗阵发性房颤发作的选择药物之一。
Objective To assess the efficacy and adverse effects of moricizine in patients with parox-ysmal atrial fibrillation （AF） and its impact on AF burden. Methods We prospectively studied the recur-rence, duration of AF and adverse reactions in patients with paroxysmal AF（ n = 212） given moricizine. Results After taken Moricizine 1.6.12 months, AF recurrence rate was only 34% .32% .35% respectively. There was no significant difference in the average heart rate,maximum heart rate and minimum heart rate, among 1.6.12 months before and after treatment, but there was a significantly decrease in AF burden. Meanwhile,there was no death and malignant ventricular arrhythmias cases during follow-up. Conclusion Moricizine can be one of the effective agents to prevent and treat paroxysmal AF.
出处
《中华心律失常学杂志》
2012年第6期407-410,共4页
Chinese Journal of Cardiac Arrhythmias
关键词
阵发性心房颤动
莫雷西嗪
不良反应
Paroxysmal atrial fibrillation
Moricizine
Adverse reactions
